<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/343A5C60-0C3D-4CEF-B900-A7C58EF9FD51"><gtr:id>343A5C60-0C3D-4CEF-B900-A7C58EF9FD51</gtr:id><gtr:name>Arla Nutrition</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC1A295F-F505-4E9F-977A-5F62E52EA5A3"><gtr:id>FC1A295F-F505-4E9F-977A-5F62E52EA5A3</gtr:id><gtr:name>GW Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/61B18DA6-342D-4115-9BAD-6A51274BC907"><gtr:id>61B18DA6-342D-4115-9BAD-6A51274BC907</gtr:id><gtr:name>P1vital Consortium</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Psychiatry</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/343A5C60-0C3D-4CEF-B900-A7C58EF9FD51"><gtr:id>343A5C60-0C3D-4CEF-B900-A7C58EF9FD51</gtr:id><gtr:name>Arla Nutrition</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC1A295F-F505-4E9F-977A-5F62E52EA5A3"><gtr:id>FC1A295F-F505-4E9F-977A-5F62E52EA5A3</gtr:id><gtr:name>GW Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E3D2D81D-2671-410B-9D1C-BBBBDA8CF466"><gtr:id>E3D2D81D-2671-410B-9D1C-BBBBDA8CF466</gtr:id><gtr:name>Johnson &amp; Johnson Ltd</gtr:name><gtr:address><gtr:line1>Foundation Park</gtr:line1><gtr:line2>Roxborough Way</gtr:line2><gtr:line4>Maidenhead</gtr:line4><gtr:line5>Berkshire</gtr:line5><gtr:postCode>SLG 3UG</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/61B18DA6-342D-4115-9BAD-6A51274BC907"><gtr:id>61B18DA6-342D-4115-9BAD-6A51274BC907</gtr:id><gtr:name>P1vital Consortium</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/382F3EEB-8130-4EB4-9046-EC4190AD6E07"><gtr:id>382F3EEB-8130-4EB4-9046-EC4190AD6E07</gtr:id><gtr:firstName>Philip</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Cowen</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12"><gtr:id>C50EE9C0-A0E3-4EB0-9EFD-C424F4204D12</gtr:id><gtr:firstName>Catherine</gtr:firstName><gtr:surname>Harmer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4B5C58CD-5356-4D61-B17F-C76D018B1FF7"><gtr:id>4B5C58CD-5356-4D61-B17F-C76D018B1FF7</gtr:id><gtr:firstName>Ciara</gtr:firstName><gtr:surname>McCabe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800905"><gtr:id>CD0426DA-D9A7-4582-94F9-F19AC12672FA</gtr:id><gtr:title>Impaired neural responses to the sight and taste of chocolate: A model of anhedonia in depression.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800905</gtr:grantReference><gtr:abstractText>Clinical depression is a common illness, often beginning in early adulthood, which can recur throughout a lifetime. The recurrent nature of clinical depression, together with the burden it places on patients and their families, makes this condition one of leading medical causes of suffering and disability. Unfortunately the medical treatment of depression is only modestly helpful and although modern antidepressant drug therapies are relatively safe they are no more effective than original antidepressant drugs discovered by chance over 50 years ago. One of the major stumbling blocks to discovering better treatments for depression is the lack of good human models of the condition. The aim of the present study is to develop a model based on a common symptom of depression, that of anhedonia. Anhedonia means loss of pleasure in things the person usually enjoys and is thought to be caused by impaired functioning of the brain pathways involved in the rewarding effects of pleasant experiences. These pathways have been well studied in healthy people using a form of magnetic brain imaging called ?fMRI? which is non-invasive and quite safe if used carefully. We have found that people at risk of depression, through a personal history of the illness, have lowered responses in these brain pathways when they see or eat or see chocolate which suggests that an impaired response of reward pathways to chocolate might be a good model of depression. The aim of the present study is to build on this idea by studying another group at high risk of depression and also to see whether certain antidepressant drugs increase the rewarding effects of pleasant experiences as would be predicted from the model. If these studies are successful it could mean that our model might be helpful in developing new drugs to treat depression and also perhaps in identifying drugs that might cause depression as side-effect</gtr:abstractText><gtr:technicalSummary>The symptom of anhedonia (loss of pleasure) is a key feature of clinical depression and is likely to be caused by abnormalities in brain reward mechanisms. Through collaborations with preclinical neuroscientists we have developed a direct and straightforward way of assessing the function of the neural pathways supporting reward by using functional magnetic resonance imaging (fMRI) to measure the neural response to the sight and taste of chocolate. The present proposal builds on our observation that people at high risk of depression, through virtue of a previous history, have abnormal neural responses in ventral striatum to both the sight and taste of chocolate. This is consistent with proposals than anhedonia may represent an endophenotypic marker of vulnerability to depression. If this is the case, impaired neural responses to chocolate could represent a valuable disease model, able to detect people at risk of depression as well as effects of treatments particularly active against anhedonic symptoms. The aim of the proposed studies is to validate the model further by assessing the neural response to chocolate in another group at high risk of depression, subjects with elevated neuroticism scores. We will also study the effects of two established antidepressants treatments to test the hypothesis that the noradrenaline potentiating agent, reboxetine, facilitates reward processes more than the serotonergic antidepressant, citalopram. Finally we will study whether the cannabinoid type 1 receptor antagonist, rimonabant, decreases the neural response to chocolate as would be predicted from its effects on reward in animals and its liability to cause high rates of depression during clinical therapeutic use.</gtr:technicalSummary><gtr:fund><gtr:end>2011-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>374267</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nuffield Department of Medicine</gtr:department><gtr:description>Oxford Biomedical Research Centre</gtr:description><gtr:id>55B3700A-7042-4963-9ED3-96D7B5F30A59</gtr:id><gtr:impact>papers submitted fro publication</gtr:impact><gtr:outcomeId>HbYPDHG5cXE-1</gtr:outcomeId><gtr:partnerContribution>provision of patients and immunological expertise</gtr:partnerContribution><gtr:piContribution>Study of the effect of interferon alpha on brain neurochemistry using MRS</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Arla Nutrition</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Nutritional Science</gtr:department><gtr:description>GMP study</gtr:description><gtr:id>9C3E1B14-AB15-42C0-A5C1-4B5E54EC2777</gtr:id><gtr:impact>Studies on effect of tyrosine free protein on dopamine function</gtr:impact><gtr:outcomeId>bnckjPb1Rnt-1</gtr:outcomeId><gtr:partnerContribution>Provision of pure protein preparations for human testing</gtr:partnerContribution><gtr:piContribution>Expertise in assessment of dopamine activity using neural and endocrine measures.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>P1vital Consortium</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>P1vital</gtr:description><gtr:id>94007CAA-5019-46E0-BA80-331C844CC9A6</gtr:id><gtr:impact>Application to MRC</gtr:impact><gtr:outcomeId>WGsxzNdLriY-1</gtr:outcomeId><gtr:partnerContribution>Intellectual and financial contribution to studies of chocolate mediated reward</gtr:partnerContribution><gtr:piContribution>A MICA grant submitted to the MRC. The contribution is from J&amp;amp;J and has been brokered by P1vital</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GW Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>GW CB1 antagonist</gtr:description><gtr:id>45A3DA4F-8CBA-4C22-BFBD-2DB68D2EF469</gtr:id><gtr:impact>Study investigation novel, plant derived, CB1 antagonist on reward and punishment</gtr:impact><gtr:outcomeId>GtihbgobuWt-1</gtr:outcomeId><gtr:partnerContribution>Provision of novel endocannibinoid ligand
Funding for study</gtr:partnerContribution><gtr:piContribution>Model for measuring the effect of drugs on neural processes of reward using fMRI</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Johnson &amp; Johnson</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Neuroscience Johnson and Johnson</gtr:department><gtr:description>Bupropion study</gtr:description><gtr:id>30B38C4A-98FB-4C64-8EB5-97BC32E1E003</gtr:id><gtr:impact>Collaboration on planned study in depressed patients</gtr:impact><gtr:outcomeId>Je4y2AHKTv5-1</gtr:outcomeId><gtr:partnerContribution>Financial contribution for the study</gtr:partnerContribution><gtr:piContribution>Models for assessment of dopamine function in emotional processing and reward</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Oxford Neuroscience Festival</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>404E19B9-DB55-407B-B66A-E9B31F38EE19</gtr:id><gtr:impact>Keynote talk at Oxford Neuroscience Festival attended by several hundred undergraduates and graduates.

Approaches by medical students to carry out electives in our laboratory.</gtr:impact><gtr:outcomeId>YNXuvrY1Kkw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC TV programme</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7F7A5424-6CFD-43AE-992D-F9B48320D678</gtr:id><gtr:impact>Further media enquiries

Dr McCabe consulted and interviewed for a BBC documentary Title &amp;quot;Britain's Favourite Foods&amp;quot; in both Oxford and Glasgow, Aug 2011. Programme will be shown Nov 2011.</gtr:impact><gtr:outcomeId>KoKatePZ9mw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Researcher initiated grant</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>GW Pharmaceuticals</gtr:fundingOrg><gtr:id>A80F43FC-80D1-4D64-A3CC-6F04E3174D06</gtr:id><gtr:outcomeId>VEf8yrM256E</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>650000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Johnson and Johnson pre-competitive award</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>E65217C9-D99E-4EEA-A08C-27341CD2482A</gtr:id><gtr:outcomeId>CZuwWT1jaBY</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7AAB1F67-73B1-4CFD-9B9E-8E01E7DE9147</gtr:id><gtr:title>Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba1cfb671d7d37216c6c9683c9dff756"><gtr:id>ba1cfb671d7d37216c6c9683c9dff756</gtr:id><gtr:otherNames>Murray E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>56d6c659161fb0.76103173</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>166E20C1-7A98-4D7E-B066-AE6B50CB0015</gtr:id><gtr:title>Effects of pramipexole on the processing of rewarding and aversive taste stimuli.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>pm_13634_24_23483198</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6960E2BF-030D-46B8-9DA1-CE3AB8F6A5FD</gtr:id><gtr:title>Neural processing of reward and punishment in young people at increased familial risk of depression.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>pm_13634_24_22704059</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A939C82-79ED-4A23-8186-1736A13B8CF7</gtr:id><gtr:title>Effects of 7 days of treatment with the cannabinoid type 1 receptor antagonist, rimonabant, on emotional processing.</gtr:title><gtr:parentPublicationTitle>Journal of psychopharmacology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc9a6a70cdcc515d2da40dad66f5d21a"><gtr:id>cc9a6a70cdcc515d2da40dad66f5d21a</gtr:id><gtr:otherNames>Horder J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0269-8811</gtr:issn><gtr:outcomeId>pm_13634_24_21406493</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378A0FB0-D33D-42D1-9094-AAA750843EF3</gtr:id><gtr:title>Reduced neural response to reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cc9a6a70cdcc515d2da40dad66f5d21a"><gtr:id>cc9a6a70cdcc515d2da40dad66f5d21a</gtr:id><gtr:otherNames>Horder J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>mADZRt7g5tH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8ECE26C5-0B27-46A1-B6CB-5E34D9AB1E55</gtr:id><gtr:title>Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn><gtr:outcomeId>ZVg4cjvaYFZ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8218FD82-BFDC-4520-88B9-C9CD7F2FD649</gtr:id><gtr:title>The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>Psychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4319dfcd8ef4be50b24fbceb03f6bfac"><gtr:id>4319dfcd8ef4be50b24fbceb03f6bfac</gtr:id><gtr:otherNames>McCabe C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0033-3158</gtr:issn><gtr:outcomeId>HkjHSMNCqyP</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A768246D-565F-4B75-BDD8-8CE1420276F8</gtr:id><gtr:title>Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin on food reward and aversion in healthy volunteers.</gtr:title><gtr:parentPublicationTitle>The international journal of neuropsychopharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3e64b971cfb601beb620109d31d9a6c"><gtr:id>c3e64b971cfb601beb620109d31d9a6c</gtr:id><gtr:otherNames>Tudge L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1461-1457</gtr:issn><gtr:outcomeId>56d6c658daaeb1.66052583</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800905</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>